BHVI has signed a three-year agreement with the AIER Eye Hospital Group, continuing their collaborative work together on key projects within the growing field of myopia management.
Collaborations with other world leading organisations is key and BHVI is delighted and proud to continue our work with AIER
BHVI has been working with AIER since 2015 at the forefront of research, development, trials and publication across the field.
“Today’s signing marks a significant step forward in our collaboration with AIER,” said Professor Padmaja Sankaridurg, Program Leader, Myopia BHVI. “AIER and BHVI are deeply committed to this ongoing partnership as we work together on key aspects of myopia management, including conducting trials and disseminating information via scientific journals for the benefit of the broader population.
“Rebecca Weng and I have been working closely with Dr Weizhang Lan and Dr Yang from AIER and we are pleased to be able to continue and further the epidemiological studies and clinical trials involving optical devices with scientists that we admire greatly.”
Currently myopia affects over a quarter of the world’s population, with the numbers highest across East Asia, and continuing to grow.
“Myopia is the fastest growing vision impairment in the world today, with the potential to impact half the world’s population by 2050,” says Yvette Waddell CEO of BHVI. “Collaborations with other world leading organisations is key and BHVI is delighted and proud to continue our work with AIER,” she added.
AIER has established more than 500 specialized hospitals globally, including covering 30 provinces across China.